Deferiprone in Friedreich ataxia: A 6-month randomized controlled trial

Annals of Neurology

Volumn 76, Issue 4, 2014, Pages 509-521

  Pandolfo, Massimo ^a   Arpa, Javier ^b   Delatycki, Martin B ^c   Le Quan Sang, Kim Hanh ^d   Mariotti, Caterina ^e   Munnich, Arnold ^d   Sanz Gallego, Irene ^b   Tai, Geneieve ^c   Tarnopolsky, Mark A ^f   Taroni, Franco ^e   Spino, Michael ^g   Tricta, Fernando ^g  

^a ERASME HOSPITAL   (Belgium)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^g ApoPharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; BLOOD; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; FRIEDREICH ATAXIA; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FRIEDREICH ATAXIA; HUMANS; IRON CHELATING AGENTS; MALE; PYRIDONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84907843433     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24248     Document Type: Article

References (37)

1. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol 2009;256(suppl 1):3-8.
2. Vankan P. Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem 2013;126(suppl 1):11-20.
3. Parkinson MH, Boesch S, Nachbauer W, et al. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J Neurochem 2013;126(suppl 1):103-117.
4. Weidemann F, Störk S, Liu D, et al. Cardiomyopathy of Friedreich ataxia. J Neurochem 2013;126(suppl 1):88-93.
5. Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci 2011;307:46-49.
6. Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem 2013;126(suppl 1):94-102.
7. Campuzano V, Montermini L, Moltò MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
8. Saveliev A, Everett C, Sharpe T, et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 2003;422:909-913.
9. Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2:551-558.
10. Yandim C, Natisvili T, Festenstein R. Gene regulation and epigenetics in Friedreich's ataxia. J Neurochem 2013;126(suppl 1):21-42.
11. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6:1771-1780.
12. Tsai C-L, Barondeau DP. Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex. Biochemistry 2010;49:9132-9139.
13. Colin F, Martelli A, Clémancey M, et al. Mammalian frataxin controls sulfur production and iron entry during de novo Fe(4)S(4) cluster assembly. J Am Chem Soc 2013;135:733-740.
14. Rouault TA. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech 2012;5:155-164.
15. Martelli A, Wattenhofer-Donzé M, Schmucker S, et al. Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet 2007;16:2651-2658.
16. Rötig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997;17:215-217.
17. Armstrong JS, Khdour O, Hecht SM. Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question. FASEB J 2010;24:2152-2163.
18. Lobmayr L, Brooks DG, Wilson RB. Increased IRP1 activity in Friedreich ataxia. Gene 2005;354:157-161.
19. Pandolfo M. Iron and Friedreich ataxia. J Neural Transm Suppl 2006;(70):143-146.
20. Sohn Y-S, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008;111:1690-1699.
21. Kakhlon O, Manning H, Breuer W, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 2008;112:5219-5227.
22. Boddaert N, Le Quan Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110:401-408.
23. Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005;64:1261-1262.
24. Lynch DR, Farmer JM, Tsou AY, et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology 2006;66:1711-1716.
25. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-211.
26. Contopoulos-Ioannidis DG, Karvouni A, Kouri I, Ioannidis JPA. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ 2009;338:a3006.
27. Regner SR, Wilcox NS, Friedman LS, et al. Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants. J Child Neurol 2012;27:1152-1158.
28. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2007;6:878-886.
29. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 2010;67:941-947.
30. Perlman SL. A review of Friedreich ataxia clinical trial results. J Child Neurol 2012;27:1217-1222.
31. Metz G, Coppard N, Cooper JM, et al. Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain 2013;136(pt 1):259-268.
32. Velasco-Sánchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011;10:1-8.
33. Arpa J, Sanz-Gallego I, Rodríguez-de-Rivera FJ, et al. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial. Acta Neurol Scand 2014;129:32-40.
34. Goncalves S, Paupe V, Dassa EP, Rustin P. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment. BMC Neurol 2008;8:20.
35. Li K, Besse EK, Ha D, et al. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet 2008;17:2265-2273.
36. Li L, Voullaire L, Sandi C, et al. Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS ONE 2013;8:e55940.
37. Pandolfo M. Treatment of Friedreich's ataxia. Expert Opin Orphan Drugs 2013;1:221-234.